Literature DB >> 18847559

Early experience with human papillomavirus vaccine introduction in the United States, Canada and Australia.

Abigail Shefer1, Lauri Markowitz, Shelley Deeks, Theresa Tam, Kathleen Irwin, Suzanne M Garland, Anne Schuchat.   

Abstract

Successful incorporation of a new vaccine into a nation's vaccination program requires addressing a number of issues, including: 1) establishing national recommendations; 2) assuring education of and acceptance by the public and medical community; 3) establishing and maintaining an appropriate infrastructure for vaccine delivery; 4) financing the vaccine and the program, in addition to political will. This article reviews the early experience with implementation of human papillomavirus (HPV) vaccination programs. It focuses on the United States of America and Canada and provides a brief report on Australia, where introduction is underway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18847559     DOI: 10.1016/j.vaccine.2008.05.065

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  Vaccines to prevent infections by oncoviruses.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Annu Rev Microbiol       Date:  2010       Impact factor: 15.500

Review 2.  The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Authors:  Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

3.  Acceptability of HPV vaccine among a national sample of gay and bisexual men.

Authors:  Paul L Reiter; Noel T Brewer; Annie-Laurie McRee; Paul Gilbert; Jennifer S Smith
Journal:  Sex Transm Dis       Date:  2010-03       Impact factor: 2.830

4.  Population-based human papillomavirus 16, 18, 6 and 11 DNA positivity and seropositivity in Chinese women.

Authors:  Jennifer S Smith; Adam K Lewkowitz; You-Lin Qiao; Jia Ji; Shangying Hu; Wen Chen; Rong Zhang; Kai Li Liaw; Mark Esser; Frank J Taddeo; Robert G Pretorius; Jerome L Belinson
Journal:  Int J Cancer       Date:  2012-01-27       Impact factor: 7.396

5.  Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area.

Authors:  Noel T Brewer; Sami L Gottlieb; Paul L Reiter; Annie-Laurie McRee; Nicole Liddon; Lauri Markowitz; Jennifer S Smith
Journal:  Sex Transm Dis       Date:  2011-03       Impact factor: 2.830

6.  Acceptability of school requirements for human papillomavirus vaccine.

Authors:  Jennifer S Smith; Noel T Brewer; Yuli Chang; Nicole Liddon; Sarah Guerry; Erica Pettigrew; Lauri E Markowitz; Sami L Gottlieb
Journal:  Hum Vaccin       Date:  2011-09

Review 7.  Human papillomavirus vaccines: current status and future prospects.

Authors:  Suzanne M Garland; Jennifer S Smith
Journal:  Drugs       Date:  2010-06-18       Impact factor: 9.546

Review 8.  Integrating clinical, community, and policy perspectives on human papillomavirus vaccination.

Authors:  María E Fernández; Jennifer D Allen; Ritesh Mistry; Jessica A Kahn
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

9.  Providers' beliefs about the effectiveness of the HPV vaccine in preventing cancer and their recommended age groups for vaccination: Findings from a provider survey, 2012.

Authors:  Z Berkowitz; M Malone; J Rodriguez; M Saraiya
Journal:  Prev Med       Date:  2015-10-24       Impact factor: 4.018

10.  HPV vaccine knowledge and beliefs among Cambodian American parents and community leaders.

Authors:  Hoai Do; Paularita Seng; Jocelyn Talbot; Elizabeth Acorda; Gloria D Coronado; Victoria M Taylor
Journal:  Asian Pac J Cancer Prev       Date:  2009 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.